Shana May
Nurse Practitioner · Coeur D Alene, IDNPI 1114699287
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 65.8% of it on its own, with 11 other manufacturers making up the rest. 2024 is the largest year on record at $2,700, more than ten times the $123 reported in 2021. Among nurse practitioner clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $44.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$322
- Neurocrine Biosciences, Inc.$205
- Axsome Therapeutics, Inc.$178
- Otsuka America Pharmaceutical, Inc.$170
- Johnson & Johnson$140
- plus $345 from 6 others
What the payments were for
- Speaking & faculty fees$1,20030%
- Travel & lodging$81521%
- Food & beverage$1,91148%
- Education$471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 23 | $2,613 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $322 |
| Neurocrine Biosciences, Inc. | 5 | $205 |
| Axsome Therapeutics, Inc. | 4 | $178 |
| Otsuka America Pharmaceutical, Inc. | 6 | $170 |
| Johnson & Johnson | 6 | $140 |
| Sunovion Pharmaceuticals Inc. | 5 | $82 |
| Lundbeck LLC | 4 | $73 |
| AbbVie | 5 | $68 |
| Alkermes, Inc. | 3 | $49 |
| Indivior Inc. | 2 | $38 |
| Corium, LLC | 2 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,973 in reported general payments places this provider in the 90th percentile of 570 nurse practitioner providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 19 | $154,519 |
| VraylarCariprazine Hcl | 26 | $36,422 |
| Invega SustennaPaliperidone Palmitate | 14 | $32,009 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $16,307 |
| TrintellixVortioxetine Hydrobromide | 30 | $14,446 |
| Paliperidone ErPaliperidone | 22 | $10,685 |
| Lurasidone Hcl | 16 | $4,968 |
| Olanzapine | 50 | $4,193 |
| Aripiprazole | 36 | $3,834 |
| Divalproex Sodium ErDivalproex Sodium | 59 | $3,133 |
| Clozapine | 28 | $2,352 |
| Atomoxetine Hcl | 14 | $2,298 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 23 | $2,263 |
| Quetiapine Fumarate | 181 | $2,085 |
| Duloxetine Hcl | 74 | $1,548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $205 | $154,51919 claims |
| AbbVieVraylar | $68 | $36,42226 claims |
| Johnson & JohnsonInvega Sustenna | $140 | $32,00914 claims |
| Alkermes, Inc.Lybalvi | $49 | $16,30711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 570 nurse practitioner providers in Idaho.
Other nurse practitioner in Coeur D Alene
- Alissa HelvikCoeur D Alene$93K
- Jamie TeskyCoeur D Alene$7K
- Ashley StroudCoeur D Alene$7K
- Lindsey AnagnostopoulosCoeur D Alene$7K
- Jennifer TorokCoeur D Alene$4K
- Krista TickemyerCoeur D Alene$4K
- Karla HansenCoeur D Alene$3K
- Laura HaneyCoeur D Alene$3K
- Brittany BransfordCoeur D Alene$3K
- Amanda WoodCoeur D Alene$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.